口头报告
吴德沛教授团队
摘要号#99
《A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment》探讨了Pimicotinib在多线系统治疗后的慢性移植物抗宿主病中的疗效和安全性，为这一难治性疾病提供了新的治疗选择。
陈苏宁教授团队
摘要号#971
卢静作为第一作者的研究《Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed AML》通过多中心随机试验，证实了维奈克拉联合地西他滨在急性髓系白血病患者中的显著疗效，特别是在提高高危患者缓解率和降低感染发生率方面表现出色。
陈苏宁教授团队
摘要号#222
窦雪晴博士作为第一作者的研究《Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive CBF-AML with KIT Mutations》提示靶向药物阿伐替尼在伴KIT基因突变的CBF-AML患者中表现出良好的疗效和安全性。这些发现将支持该疗法在AML中的应用，为个体化治疗提供了宝贵的临床数据支持。
唐晓文教授团队
摘要号#683
马云菊博士作为第一作者的研究《Sequential Infusion of Anti-CD19 and Anti-BCMA CAR-T in Refractory Immune-Mediated Platelet Transfusion Refractoriness》表明CAR-T细胞治疗riPTR和清除抗体方面既安全又有效，使其在抗体介导的疾病治疗中具有广泛应用前景。CAR-T细胞治疗也是一项有前景的清DSA策略，适用于具有高移植排斥风险的同种异体造血干细胞移植和器官移植。本临床试验证明，通过单次CAR-T细胞治疗，抗体介导的疾病可能实现长期缓解，将治疗原则从免疫抑制转向免疫重建。
唐晓文教授团队
摘要号#270
陈晓倩博士作为第一作者的研究《Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen for High-Risk ALL》显示VA联合改良BuCy的强化预处理方案并未增加治疗相关毒性，显著降低了移植后复发率，并延长了高危或难治/复发ALL患者的长期生存，为患者带来了新希望。
壁报展示
按通讯作者姓氏字母顺序排列
吴德沛 教授通讯作者
Poster#1676，第一作者：黄海雯
题目: Clinical Characteristics and Treatment Outcomes in 104 Cases of NK/T-Cell Lymphoma
Poster#2879，第一作者：王荧
题目: A First-in-Human Study of the Menin-KMT2A Inhibitor BN104 in Relapsed/Refractory AML
Poster#3515，第一作者：茹煜华
题目: Subcutaneous Abatacept for acute graft-versus-host disease prophylaxis after haploidentical donor hematopoietic cell transplantation
Poster#3535，第一作者：刘吟
题目: Autologous Fecal Microbiota Transplantation as GVHD Prophylaxis in Haplo-HSCT
Poster#4442，第一作者：黄海雯
题目: Study of Autologous Versus Allogeneic Stem Cell Transplantation in High-Risk NK/T-Cell Lymphoma
陈苏宁 教授通讯作者
Poster #1781，第一作者：蔡文治
题目: A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Poster #4893，第一作者：乔曼
题目: Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial
傅琤琤 教授通讯作者
Poster#1997，第一作者：傅琤琤
题目: Interim Analysis of DARA VRD in TE-NDMM Patients Refusing ASCT
Poster#4750，第一作者：颜灵芝
题目: Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma
Poster#4766，第一作者：施晓兰
题目: Five-Year Follow-up of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Multiple Myeloma
Poster#4843，第一作者：傅琤琤
题目: A First-in-Human study of CT0590, a CAR T-cell Therapy Targeting BCMA and NKG2A, in Relapsed/Refractory Multiple Myeloma
韩 悦 教授通讯作者
Poster#1167，第一作者：戚嘉乾
题目：Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia
Poster#3494，第一作者：康慧珠
题目：Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL
黄海雯 教授通讯作者
Poster#3113，第一作者：尤涛
题目：Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis
唐晓文 教授通讯作者
Poster#3384，第一作者：陈娟
题目: BIRD Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma
Poster#3493，第一作者：崔巍
题目: VA combined with mBuCy conditioning regimen followed by allo-HSCT can improve survival of high-risk AML patients: a prospective, single-center, single-arm clinical trial
Poster#4197，第一作者：郦梦云
题目: CD19/CD22 CAR-T Therapy as First-Line Treatment for High-Risk Philadelphia Chromosome-Negative ALL
Poster#4284，第一作者：李雪锴
题目: How to Improve the Efficacy of Venetoclax and Azacitidine for Newly Diagnosed AML? A Phase 2 Trial
Poster#4836，第一作者：尹佳
题目: Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
王 荧 教授通讯作者
Poster#4287，第一作者：冯梓瑜
题目: Hypomethylating Agent and Venetoclax in CBFβ::MYH11(+) AML
薛胜利 教授通讯作者
Poster#1484，第一作者：刘芳彤，万超玲
题目: Venetoclax with Hypomethylating Agents Compared with Priming Regimens for AML with Myelodysplasia Related Changes: A Retrospective Study
Poster#1507，第一作者：谭凯文
题目: Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens for AML with Mature Monocytic Immunophenotype
Poster#1527，第一作者：万超玲
题目: Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes
Poster#4840，第一作者：王子豪
题目: CD22/CD19 CAR-T and Auto-HSCT “Sandwich” Strategy as Consolidation Therapy for Ph-Negative B-ALL
殷 杰 教授通讯作者
Poster#3940，第一作者：何海菊
题目: Obinutuzumab is a promising alternative for the treatment of relapsed or refractory autoimmune hematological disorders
胡绍燕 教授通讯作者
Poster#3486，第一作者：张森林
题目：Comparison of Rabbit ATLG and ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anemia
此次多项研究入选ASH年会，不仅体现了我院在血液学研究中的实力，更为前沿技术的推广和优化患者治疗方案奠定了基础。未来，苏大附一院将继续深耕血液学领域的创新研究，不断推进临床实践，造福更多血液病患者。